Table of Contents
PPT Slide
Clinical Pharmacokinetics
Sirolimus Pharmacokinetics
Rapid Absorption Rate After Single Oral Doses in Stable Renal Transplant Patients
Time to Steady State and Terminal Half-Life Are Consistent Among Ascending Multiple Oral Dose Regimens of RAPAMUNE
Whole Blood Sirolimus Dose Proportionality in Stable Renal Transplant Patients After Single Oral Doses of RAPAMUNE
Sirolimus Distribution
Sirolimus Metabolism and Elimination
Demographic Factors Have No Substantial Effect on Sirolimus Pharmacokinetics
Other Factors Affecting Sirolimus Pharmacokinetics
Effect of Other Drugs on the Exposure (AUC) of Sirolimus
Increases in Sirolimus AUC After Administration of Cyclosporine
Whole Blood Sirolimus Pharmacokinetic Parameters* in De Novo Renal Transplant Patients
Whole Blood Sirolimus AUC Versus Cmin* for Combined RAPAMUNE 2-mg and 5-mg Dose Groups
Equal Exposure to Sirolimus in Black and Non-Black Patients
Sirolimus Exposure in De Novo Renal Transplant Patients Remains Constant Over Time
Mean Cyclosporine Levels Were Not Different Between Treatment Groups
RAPAMUNE Reduces Dose Requirements of Cyclosporine
Clinical Pharmacokinetics Conclusions I
Clinical Pharmacokinetics Conclusions II
Well Defined Pharmacokinetic Behavior in Renal Transplant Recipients
|